Page last updated: 2024-11-08

didesmethylcitalopram

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

didesmethylcitalopram: metabolite of citalopram; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID162976
CHEMBL ID3544716
CHEBI ID80604
SCHEMBL ID3288673
MeSH IDM0178225

Synonyms (24)

Synonym
5-isobenzofurancarbonitrile, 1-(3-aminopropyl)-1-(4-fluorophenyl)-1,3-dihydro-
didemethylcitalopram
62498-69-5
didesmethylcitalopram
FT-0666667
1-(3-aminopropyl)-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile
unii-ze9yvi4zee
ze9yvi4zee ,
5-isobenzofurancarbonitrile,1-(3-aminopropyl)-1-(4-fluorophenyl)-1,3-dihydro-
1-(3-aminopropyl)-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile
CHEBI:80604 ,
SCHEMBL3288673
CHEMBL3544716
Q27149648
didemethylcitalopram pound>>didesmethylcitalopram oxalate
BCP28171
DTXSID50978083
1-(3-aminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
rac-didesmethylcitalopram
lu 11-161
(s)-n-didesmethyl citalopram oxalate
didesmethyl citalopram-d4
rac didemethyl citalopram
discontinued. see d439476

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Comparable pharmacokinetic variability was noted for (+)-(S)-, (-)-(R)- and rac-citalopram."( Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans.
Grollier, G; Larsen, F; Poulsen, M; Priskorn, M; Segonzac, A; Sidhu, J, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Enantiomeric (S/R) serum concentration ratios for citalopram were always less than unity and were constant during the steady-state dosing interval."( Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans.
Grollier, G; Larsen, F; Poulsen, M; Priskorn, M; Segonzac, A; Sidhu, J, 1997
)
0.3
"The AUC of S-, but not R-(CT) was found to be significantly higher in PM of mephenytoin compared to EMs, PMs may need a lower dosage of CT."( Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes.
Bertilsson, L; Gustafsson, LL; Herrlin, K; Tybring, G; Widén, J; Yasui-Furukori, N, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
organic amino compoundA compound formally derived from ammonia by replacing one, two or three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Citalopram and Escitalopram Pathway, Pharmacokinetics44
Citalopram Action Pathway3724
Citalopram Metabolism Pathway715

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (16.67)18.2507
2000's6 (50.00)29.6817
2010's4 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.39 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (8.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (8.33%)4.05%
Observational0 (0.00%)0.25%
Other10 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]